An effective vaccine against colon cancer in mice: Use of recombinant adenovirus interleukin-12 transduced dendritic cells

Figure 4 Protective effect of CT26 TP AdVIL-12/DCs in CT26 tumor models. Naïve BALB/c mice were injected s.c. in their abdominal walls on d 0, 7, and 14 with 1 × 10⁶ DCs vaccination: CT26 TP AdVIL-12/DCs or CT26 TP DCs. Mice injected with unstimulated DCs, CT26 tumor lysate alone, and PBS alone were used as controls. On d 21, each mouse was challenged s.c. with a lethal dose of 2 × 10⁶ CT26 cells. Survival was observed after the challenge with tumor cells. Survival rate was compared with a log-rank test of Kaplan-Meier curves. The survival advantage conferred by the CT26 TP AdVIL-12/DC was statistically significant compared with CT26 TP DCs group and other control groups (Kaplan-Meier, P < 0.05).